KIRhub 2.0· v2

Nilotinib

fb7ff0a5-124c-54e2-a9f8-641077094c0e · FDA Approved · targets BCR_ABL, ABL1, ABL2_ARG

Nilotinib

MeasuredReference

Nilotinib targets DDR2, EPHB1, EPHB2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

DDR2 EPHB1 EPHB2 DDR1 RAF1

Top hallmarks

tumor promoting inflammation3.4k
evading apoptosis2.9k
proliferation2.8k

Top pathways disrupted

apical junction7.2k
pi3k akt mtor signaling6.2k
allograft rejection6.0k

Resistance landscape — Nilotinib

MeasuredReference

3 known oncogenic variants exist on Nilotinib's top targets — see detail for inhibition impact.

DDR2 2 known variants
- DDR2 (N456S)
- DDR2 (T654M)
RAF1 1 known variant
- RAF1 (R391W)

Open in new tab